Pancreatic Cancer Research

ResearcherOita Prefectural HospitalActive in the last 2 years

Tohru Utsunomiya

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5032479078, A5110256843. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
23
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper

Papers 8

  1. Ectopic pancreatic adenocarcinoma in Meckel's diverticulum: a case report. Last author DOI 10.1186/s40792-024-01843-8↗
  2. Effect of duration of adjuvant chemotherapy with S-1 (6 versus 12 months) for resected pancreatic cancer: the multicenter clinical randomized phase II postoper… Co-author DOI 10.1007/s10147-023-02399-7↗
  3. DUPAN-2 as a Risk Factor of Early Recurrence After Curative Pancreatectomy for Patients With Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000002209↗
  4. Elevated Preoperative DUPAN-2 Level Predicts Locoregional Recurrence After Pancreatectomy in Patients With Pancreatic Ductal Adenocarcinoma. Last author DOI 10.21873/anticanres.15688↗
  5. Prognostic significance of preoperative PNI and CA19-9 for pancreatic ductal adenocarcinoma: A multi-institutional retrospective study. Co-author DOI 10.1016/j.pan.2021.08.003↗
  6. The novel driver gene ASAP2 is a potential druggable target in pancreatic cancer. Co-author DOI 10.1111/cas.14858↗
  7. Changes of immunological parameters with administration of Japanese Kampo medicine (Juzen-Taihoto/TJ-48) in patients with advanced pancreatic cancer. Last author DOI 10.1007/s10147-013-0529-6↗
  8. Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-α on pancreatic cancer cells. Co-author DOI 10.1007/s10147-011-0246-y↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shoichi Inokuchi · 2 shared papers, 2022–2024 · strength 0.37
  2. Atsushi Sasaki · 2 shared papers, 2022–2023 · strength 0.34
  3. Keishi Sugimachi · 2 shared papers, 2021–2023 · strength 0.25
  4. Tomoharu Yoshizumi · 2 shared papers, 2021–2023 · strength 0.25
  5. Shinji Itoh · 2 shared papers, 2021–2023 · strength 0.25
  6. Mototsugu Shimokawa · 1 shared paper, 2023 · strength 0.15
  7. Hiromitsu Hayashi · 1 shared paper, 2023 · strength 0.15
  8. Hideo Baba · 1 shared paper, 2023 · strength 0.15
  9. Kenichiro Araki · 1 shared paper, 2023 · strength 0.15
  10. Tadashi Uwagawa · 1 shared paper, 2023 · strength 0.15
  11. Hiroto Kayashima · 1 shared paper, 2023 · strength 0.15
  12. Hiroshi Takamori · 1 shared paper, 2023 · strength 0.15
  13. Masaki Mori · 1 shared paper, 2021 · strength 0.11
  14. Tomohiro Iguchi · 1 shared paper, 2021 · strength 0.11
  15. Masafumi Nakamura · 1 shared paper, 2021 · strength 0.10
  16. Atsushi Fujii · 1 shared paper, 2021 · strength 0.10
  17. Takao Ohtsuka · 1 shared paper, 2021 · strength 0.10
  18. Koshi Mimori · 1 shared paper, 2021 · strength 0.10
  19. Shuichi Iwahashi · 2 shared papers, 2011–2014 · strength 0.07
  20. Yu Saito · 2 shared papers, 2011–2014 · strength 0.07
  21. Tetsuya Ikemoto · 2 shared papers, 2011–2014 · strength 0.07
  22. Mitsuo Shimada · 2 shared papers, 2011–2014 · strength 0.07
  23. Koji Sugimoto · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.